# Errik Anderson

> Errik Anderson is the founder and CEO of Alloy Therapeutics, a Lexington, Massachusetts biotech he built around a single idea: stop selling drugs and start selling access to the tools that make them. A bioengineer and serial entrepreneur, he has founded or co-founded seven venture-backed biotech companies - Adimab, Alloy, Compass Therapeutics, Alector, Arsanis, and Avitide among them - whose technologies have helped discover more than 90 therapeutic antibodies now approved or in FDA review. Alloy reinvests 100% of its revenue into science and, by design, can never be sold. Outside the lab, Anderson co-owns the New England Free Jacks pro rugby team and has chaired Major League Rugby's Board of Governors.

- **Role:** Founder & CEO at Alloy Therapeutics
- **Organizations:** Alloy Therapeutics, Inc., 82VS (82 Venture Studio), Ulysses Diversified Holdings, Adimab, Compass Therapeutics, New England Free Jacks, Major League Rugby
- **Nationality:** American
- **Education:** A.B. in Economics, Dartmouth College, MBA (Tuck Scholar), Tuck School of Business at Dartmouth, Graduate studies, M.S. Biomolecular/Bioengineering (did not finish), Thayer School of Engineering at Dartmouth
- **Known for:** Founded or co-founded seven venture-backed biotech companies, Technologies from his companies helped discover 90+ therapeutic antibodies approved or in FDA review, Built Alloy Therapeutics into a 150-person company with 150+ partnerships across pharma, biotech, and academia

## Career timeline

- **early career** — Worked in venture capital at Lehman Brothers Venture Capital and in marketing at Bristol-Myers Squibb
- **2007** — Co-founded Adimab with Dartmouth/Thayer professor Tillman Gerngross; served as COO
- **2010s** — Founded or co-founded multiple biotech ventures: Compass Therapeutics, Alector, Arsanis, Avitide
- **2017** — Founded Alloy Therapeutics to democratize access to biologics discovery tools and services
- **2018** — Joined Biomatics Capital Partners as a venture investor
- **2018** — Co-founded the New England Free Jacks professional rugby team
- **ongoing** — Launched 82VS venture studio; serves as CEO of Ulysses Diversified Holdings single-family office
- **2026-04** — Alloy raised a Series E round ($40M tranche reported); total funding ~$222M

## Achievements

- Founded or co-founded seven venture-backed biotech companies
- Technologies from his companies helped discover 90+ therapeutic antibodies approved or in FDA review
- Built Alloy Therapeutics into a 150-person company with 150+ partnerships across pharma, biotech, and academia
- Structured Alloy so its controlling stock can never be sold, reinvesting 100% of revenue into science
- Co-owner and Chairman of the New England Free Jacks; former Chairman of Major League Rugby's Board of Governors
- Created 82VS venture studio to lower barriers for first-time biotech founders

## Latest updates

- **2026-04** — Alloy Therapeutics' most recent reported raise (Series E), with a $40M tranche; total funding reported around $222M.
- **2026-05** — Updated leadership profile and photo published on the Alloy Therapeutics website.

## Links

- Website: https://alloytx.com
- LinkedIn: http://www.linkedin.com/in/errikanderson
- Twitter/X: https://twitter.com/errikanderson

---

Profile page: https://yespress.io/errik-anderson
Published by YesPress — https://yespress.io
Last updated: 2026-06-12